Table 2.
Persistence on PrEP medication in year 1 (zero to twelve months), year 2 (twelve to twenty‐four months), and initiation to year 2 (zero to twenty‐four months) among individuals who initiated PrEP in the United States, 2015 for selected variables
| PrEP initiation | Persistence in year 1 (zero to twelve months) | Persistence in year 2 (thirteen to twenty‐four months) | Persistence from initiation to year 2 (zero to twenty‐four months) | ||||
|---|---|---|---|---|---|---|---|
| n | n | Percent persistent | n | Percent persistent | n | Percent persistent | |
| All | 7148 | 4030 | 56% | 2521 | 63% | 2951 | 41% |
| Age | |||||||
| 18 to 24 | 784 | 339 | 43% | 183 | 54% | 227 | 29% |
| 25 to 29 | 1552 | 815 | 53% | 452 | 55% | 539 | 35% |
| 30 to 39 | 2521 | 1409 | 56% | 872 | 62% | 1041 | 41% |
| 40 to 49 | 1432 | 912 | 64% | 621 | 68% | 704 | 49% |
| 50+ | 855 | 553 | 65% | 392 | 71% | 439 | 51% |
| Gender | |||||||
| Men | 6900 | 3944 | 57% | 2479 | 63% | 2901 | 42% |
| Women | 244 | 84 | 34% | 41 | 49% | 49 | 20% |
To be considered persistent, individuals must have had 16 days of medication available per calendar month for three‐quarters of months in each period. Only individuals persistent at one year of follow‐up (months 0 to 12) were eligible to be considered persistent at two years (months 13 to 24). Variables in this table are significantly associated with PrEP discontinuation; see Table 3 for more detail. Some data points are missing for up to four individuals.